Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07768267 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome

StatusNot Yet Recruiting
PhasePhase 2
Started2026-10-01
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2026 → Dec 31, 2027
See other at-risk trials from Johns Hopkins University

Amendment history

2026-09-03
critical
Study Status v3
Primary completion pushed: 2026-12-31 → 2027-12-31
Completion pushed: 2027-08-10 → 2027-12-31
Start date2026-09-01→2026-10-01
2026-08-25
minor
Study Status, Contacts/Locations v2
Study sitescontacts updated at 1 of 1 site
2026-08-18
minor
Study Status, Contacts/Locations v1
Re-verified, no change to tracked fields
2026-08-13
minor
Original filing
The goal of this clinical trial is to learn if an herbal supplement called Biocidin REMOVE can clear small intestinal bacterial overgrowth (SIBO) in adults with irritable bowel syndrome (IBS). SIBO means there are too many bacteria in the small intestine. It can make IBS symptoms worse. This is a small first study, called a pilot study. Its results will help researchers plan larger studies. The main questions it aims to answer are: Does Biocidin REMOVE clear SIBO? Does it lower IBS symptoms and improve quality of life? Does it change the mix of bacteria in the gut? Researchers will compare Biocidin REMOVE to a placebo. A placebo is a look-alike capsule that contains no active ingredients. Neither the participants nor the research team will know who gets which one. About 40 adults age 18 and older will take part. Participants will: Take capsules by mouth twice a day for about 5 weeks. Participants will start with a low dose and build up to 2 capsules twice a day. Take a breath test at the start and at the end of treatment. This test checks for SIBO. Collect a stool sample at home at the start and at the end of treatment. Answer questions about symptoms and quality of life. Report what was eaten during the study. Come back for one check-in about 4 weeks after treatment ends.
Trial Details
NCT Number NCT07768267
Lead Sponsor Johns Hopkins University
Collaborators: Biocidin
Conditions Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Enrollment 40 participants
Start Date 2026-10-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-04